A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome

Fragile X Syndrome Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-controlled, Two-Part Study of High and Low Dose BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05163808
• Other study ID #: BPN14770-CNS-204
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: March 29, 2022
• Est. completion date: July 2024

Study information

• Verified date: February 2024
• Source: Tetra Discovery Partners
• Contact: CEO
• Phone: 616-224-0084
• Email: info[@]tetratherapeutics.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a 2-part study, with each part having a unique set of objectives for male adolescents aged 9 to < 18 years with fragile X syndrome (FXS). Part 1 is an open-label, single-dose, pharmacokinetics (PK) assessment of BPN14770 25 mg and 50 mg, while Part 2 is double-blind (DB) and randomized between two treatment groups (Study Drug and Placebo).

Description:

In amendment 4 the enrollment age range what changed to allow enrollment in participants as young as 9 years of age. This only affects Part 2 as Part 1 was completed prior to this amendment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: July 2024
• Est. primary completion date: February 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 9 Years to 18 Years

Eligibility

Inclusion Criteria:

• 1. Patient is male adolescent aged 9 to < 18 years. 2. Patient has FXS with a molecular genetic confirmation of the full fragile X mental retardation-1 (FMR1) mutation (= 200 CGG repetitions).

3. Current treatment with = 3 prescribed psychotropic medications. Anti-epileptic medications are permitted and are not counted as psychotropic medications if they are used for treatment of seizures. Anti-epileptics for other indications, such as the treatment of mood disorders, count towards the limit of permitted medications. If the subject is on 3 prescribed psychoactive medications and, in addition, is taking either a psychoactive over-the-counter medication (eg, melatonin, Benadryl, etc.) or CBD products, the investigator is encouraged to discuss eligibility with the medical monitor.

4. Permitted concomitant psychotropic medications must be at a stable dose and dosing regimen for at least 4 weeks before screening and must remain stable during the period between screening and the commencement of study drug. Every effort should be made to keep dosing stable throughout the study.

5. Anti-epileptic medications must be at a stable dose and dosing regimen for 12 weeks before screening and must remain stable during the period between screening and the commencement of study drug. Every effort should be made to keep dosing stable throughout the study.

6. Patients with a history of seizure disorder who are currently receiving treatment with anti-epileptics must have been seizure-free for 3 months before screening or must be seizure-free for 2 years if not currently receiving anti-epileptics.

7. Behavioral and other non-pharmacological treatments/interventions must be stable for 4 weeks before screening and must remain stable during the period between screening and the commencement of study drug, and throughout the study. Minor changes in hours or times of therapy that are not considered clinically significant will not be exclusionary. Changes in therapies provided through a school program, due to school vacations, are allowed.

8. Patient must be willing to practice barrier methods of contraception while on study, if sexually active. Abstinence is also considered a reasonable form of birth control in this study population.

9. Patient has a parent(s), legal authorized guardian(s), or consistent caregiver(s).

10. Patient and caregiver are able to attend the clinic regularly and reliably. 11. Patient's parent(s), legal authorized guardian(s), or consistent caregiver(s) is able to understand and sign an informed consent form to participate in the study.

12. Patient must provide assent for participation in the study if the patient has the cognitive ability to provide assent.

13. To participate in the Part 1 PK only: subjects must be able to swallow capsules.

Exclusion Criteria:

Diagnosis and main criteria for inclusion:

The eligibility criteria are the same for all parts of the study except for Part 1 (PK), where patients must be able to swallow capsules and must weigh at least 75 lbs (34 kg) to receive the 50 mg dose.

Patient Inclusion Criteria

1. Patient is male adolescent aged 12 to < 18 years.

2. Patient has FXS with a molecular genetic confirmation of the full fragile X mental retardation-1 (FMR1) mutation (= 200 CGG repetitions).

3. Current treatment with = 3 prescribed psychotropic medications. Anti-epileptic medications are permitted and are not counted as psychotropic medications if they are used for treatment of seizures. Anti-epileptics for other indications, such as the treatment of mood disorders, count towards the limit of permitted medications.

4. Permitted concomitant psychotropic medications must be at a stable dose and dosing regimen for at least 4 weeks before screening and must remain stable during the period between screening and the commencement of study drug.

5. Anti-epileptic medications must be at a stable dose and dosing regimen for 12 weeks before screening and must remain stable during the period between screening and the commencement of study drug.

6. Patients with a history of seizure disorder who are currently receiving treatment with anti-epileptics must have been seizure-free for 3 months before screening or must be seizure-free for 2 years if not currently receiving anti-epileptics.

7. Behavioral and other non-pharmacological treatments/interventions must be stable for 4 weeks before screening and must remain stable during the period between screening and the commencement of study drug, and throughout the study. Minor changes in hours or times of therapy that are not considered clinically significant will not be exclusionary. Changes in therapies provided through a school program, due to school vacations, are allowed.

8. Patient must be willing to practice barrier methods of contraception while on study, if sexually active. Abstinence is also considered a reasonable form of birth control in this study population.

9. Patient has a parent(s), legal authorized guardian(s), or consistent caregiver(s).

10. Patient and caregiver are able to attend the clinic regularly and reliably.

11. Patient's parent(s), legal authorized guardian(s), or consistent caregiver(s) is able to understand and sign an informed consent form to participate in the study.

12. Patient must provide assent for participation in the study if the patient has the cognitive ability to provide assent.

13. To participate in the Part 1 PK only: patients must be able to swallow capsules.

Patient Exclusion Criteria

1. Inability to successfully complete the NIH-TCB picture vocabulary and oral reading assessments at screening and baseline for Part 2 (DB). Patient must be able to complete these assessments at baseline to be randomized into Part 2; care should be taken that a patient enrolled into Part 1 (PK) possesses this ability if their desire is to continue to Part 2. The ability to complete the NIH-TBC oral reading and picture vocabulary subtest at baseline is defined as the ability to complete both subtests, with (1) confirmation from the clinician administering that the test administrations are valid (noted on the administration form), and (2) generation of valid test scores for each test.

2. History of, or current cardiovascular, renal, hepatic, respiratory, gastrointestinal, psychiatric, neurologic, cerebrovascular, or other systemic disease that would place the patient at risk or potentially interfere with the interpretation of the safety, tolerability, or efficacy of the study drug.

• Common conditions such as mild hypertension, etc. are allowed per the PI's judgment as long as they are stable and controlled by medical therapy that is constant for at least 4 weeks before randomization.

3. Renal impairment, defined as serum creatinine > 1.25 × ULN at screening.

4. Cirrhosis, unstable chronic liver disease or acute liver disease. Hepatic impairment, defined as alanine aminotransferase or aspartate aminotransferase elevation > 2 × ULN at screening. Note: liver function tests may be repeated after 1 week to evaluate return to acceptable limits; if liver function tests remain elevated, patient is ineligible to participate. Subjects with stable chronic hepatitis B on oral anti-viral therapy and subjects cured of chronic hepatitis C may be allowed. Subjects with Gilbert syndrome are allowed.

5. Clinically significant abnormalities, in the PI's judgment, in safety laboratory tests, vital signs, or 12-lead ECG, as measured during screening.

6. History of alcohol abuse at any time in life or history of other substance abuse within the past year, according to PI's assessment.

7. Significant hearing or visual impairment that may affect the patient's ability to complete the test procedures.

8. Concurrent major psychiatric condition (eg, major depressive disorder, schizophrenia, or bipolar disorder) as confirmed by the PI. Patients with additional diagnosis of autism spectrum disorder or anxiety disorder will be allowed.

9. Subject has active diseases that would interfere with participation, such as acquired immunodeficiency disorder, hepatitis C, hepatitis B, or tuberculosis.

10. Subject is planning to commence psychotherapy or CBT within 4 weeks prior to screening.

11. Patient is an immediate family member of anyone employed by the sponsor, PI, or study staff.

12. Patient has weight < 25 kg or a BMI greater than the 97th percentile for his age according to the Centers for Disease Control and Prevention (refer to Appendix 1). To participate in the Part 1 cohort receiving 50 mg dose, patient must weigh = 75 lbs (34 kg).

13. Patient has participated in another clinical trial within the 30 days before screening.

-

Related Conditions & MeSH terms

• Fragile X Syndrome
• Syndrome

Intervention

Drug:
• zatolmilast
Subjects will receive a 15 mg or 25 mg dose of zatolmilast (BPN14770) or placebo
• Placebo
Placebo

Locations

Country	Name	City	State
United States	Emory University School of Medicine	Atlanta	Georgia
United States	Kennedy Krieger Institute	Baltimore	Maryland
United States	Rush University Medical Center	Chicago	Illinois
United States	Cincinatti Children's Hospital Medical Center	Cincinnati	Ohio
United States	Children's Hospital Colorado	Denver	Colorado
United States	Greenwood Genetic Center	Greenwood	South Carolina
United States	Amnova Clinical Research	Irvine	California
United States	University of Kansas Medical Center	Kansas City	Kansas
United States	Suburban Research Associates	Media	Pennsylvania
United States	Icahn School of Medicine at Mount Sinai Hospital	New York	New York
United States	CHOC Thompson Autism Center	Orange	California
United States	UC Davis	Sacramento	California
United States	University of Utah and Primary Childrens Hospital	Salt Lake City	Utah
United States	Clinic for Special Children	Strasburg	Pennsylvania
United States	U Mass	Worcester	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Tetra Discovery Partners

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	NIH Toolbox Cognitive Battery cognition crystallized composite score	The change from baseline to Week 13 in the NIH Toolbox Cognitive Battery cognition crystallized composite score (NIH-TCB CCC), which is calculated from the Picture Vocabulary and Oral Reading domains.	13 Weeks
Secondary	NRS patient-specific behaviors within the domains of Daily Function, Language, and Academic Skills.	Change from baseline to Week 13 in Numerical rating scale (NRS) scores based on patient-specific behaviors within the domains of Daily Function, Language, and Academic Skills.	13 Weeks
Secondary	CaGI-I for the general domains of Daily Function, Language, and Academic Skills.	Change from baseline to Week 13 Caregiver Global Impression of Improvement (CaGI-I) for the general domains of Daily Function, Language, and Academic Skills.	13 Weeks
Secondary	Investigator rated (CGI-I) for the general domains of Daily Function, Language, and Academic Skills	Change from baseline to Week 13 Clinical Global Impression Improvement - Investigator rated (CGI-I) for the general domains of Daily Function, Language, and Academic Skills	13 Weeks
Secondary	NRS scores based on patient-specific behaviors within the domain of Emotions/Behaviors	Change from baseline to Week 13 NRS scores based on patient-specific behaviors within the domain of Emotions/Behaviors	13 Weeks
Secondary	CaGI-I for the general domain of Emotions/Behaviors	Change from baseline to Week 13 CaGI-I for the general domain of Emotions/Behaviors	13 Weeks
Secondary	The NIH-TCB domains of Picture Vocabulary, Oral Reading Recognition, and Pattern Comparison Processing Speed	Change from baseline to Week 13 the NIH-TCB domains of Picture Vocabulary, Oral Reading Recognition, and Pattern Comparison Processing Speed	13 Weeks
Secondary	Vineland-3 Adaptive Behavior Scale (Vineland-3)	Change from baseline to Week 13 Vineland-3 Adaptive Behavior Scale (Vineland-3)	13 Weeks
Secondary	Verbal Knowledge test from the Stanford Binet (ed 5) (SB-5) IQ assessment	Change from baseline Verbal Knowledge test from the Stanford Binet (ed 5) (SB-5) IQ assessment	13 Weeks